{
    "clinical_study": {
        "@rank": "100641", 
        "arm_group": [
            {
                "arm_group_label": "Ginkgo Synergy\u00ae and Choline", 
                "arm_group_type": "Experimental", 
                "description": "Ginkgo Synergy\u00ae (120 mg/day Ginkgo biloba leaf with 80 mg/day Ginkgo biloba whole extract combined with 40 mg/day Grape Seed extract) and Choline (700 mg choline/day)"
            }, 
            {
                "arm_group_label": "OPC Synergy\u00ae and Catalyn", 
                "arm_group_type": "Experimental", 
                "description": "OPC Synergy\u00ae (100 mg/day of Grape Seed extract with 50 mg/day Green Tea extract (60% catechins)) and Catalyn\u00ae (1,248 IU/day of Vitamin D, 4,800 IU/day of Vitamin A, combined with vitamin C, thiamine, riboflavin, and vitamin B6)"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "cellulose pills to simulate actual products"
            }
        ], 
        "brief_summary": {
            "textblock": "A six-month study which investigated the effect of Ginkgo Synergy\u00ae and Choline or OPC\n      Synergy\u00ae and Catalyn\u00ae on cognitive and immune function markers and quality of life among\n      healthy older adults with no history of significant cognitive deficits"
        }, 
        "brief_title": "Evaluating Whole Foods Supplementation on Cognition", 
        "completion_date": {
            "#text": "December 2011", 
            "@type": "Actual"
        }, 
        "condition": "Improvement of Cognitive Functions", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  60 years of age and older\n\n          -  English speaking\n\n          -  Not living in a skilled or intermediate care level nursing facility\n\n          -  No use of dietary supplements for cognitive functioning two weeks before enrolling in\n             the study and during the length of the trial\n\n          -  A Mini-Mental State Exam (MMSE) score \u2265 23\n\n        Exclusion Criteria:\n\n          -  A cognitive deficit greater than that indicated according to the MMSE score\n\n          -  A clinical diagnosis of AD and/or related disorders\n\n          -  A psychiatric diagnosis of schizophrenia, other psychotic disorders, bipolar\n             disorder, major depression with psychotic features, delirium, and alcohol or\n             substance abuse/dependence\n\n          -  Bleeding disorders\n\n          -  Aphasia or sensory, motor, and/or visual disturbances that would have interfered with\n             psychometric tests\n\n          -  Gastrointestinal disorders causing impaired absorption of the study supplements\n\n          -  Insulin-dependent diabetes\n\n          -  Major conditions such as cardiovascular, pulmonary, renal, thyroid, hepatic,\n             gastrointestinal, or seizure\n\n          -  Hematologic or oncologic disorders treated with chemotherapy in the previous two\n             years\n\n          -  Active chemotherapy or radiation treatment for cancer\n\n          -  Current cigarette smoking\n\n          -  More than three major medical or psychiatric hospitalizations in the past year\n\n          -  Diagnosis of a terminal illness\n\n          -  A T score > 70 on the Global Severity Index of the Brief Symptoms Inventory (BSI)\n\n          -  A score \u2265 29 on the Beck Depression Inventory-II (BDI) (15)\n\n          -  Prescription and OTC sympathomimetic amines and antihistamines within 2 days of an\n             assessment visit\n\n          -  Cognition enhancing drugs consumption such as Donepezil, Rivastigmine, Galantamine,\n             and Tacrine\n\n          -  Coumadin, tricyclic antidepressants, antipsychotics, and anticonvulsants\n\n          -  Cognition-enhancing supplements, herbs, or antioxidants that could not be stopped\n             during the trial\n\n          -  Participating in a concurrent trial for drugs, supplements, or treatment that affects\n             behavior or cognitive function"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "60 Years"
        }, 
        "enrollment": {
            "#text": "97", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01672359", 
            "org_study_id": "20090985"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ginkgo Synergy\u00ae and Choline", 
                "description": "3 tablets 2 times per day with breakfast and dinner over 6 months", 
                "intervention_name": "Ginkgo Synergy\u00ae and Choline", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "OPC Synergy\u00ae and Catalyn", 
                "description": "3 tablets 2 times per day with breakfast and dinner over 6 months", 
                "intervention_name": "OPC Synergy\u00ae and Catalyn", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Choline"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "cognitive functioning", 
            "immune function", 
            "cytokines", 
            "growth factors", 
            "quality of life", 
            "dietary supplementation", 
            "Ginkgo biloba", 
            "Improvement of cognitive functions of healthy older adults with no history of significant cognitive deficits"
        ], 
        "lastchanged_date": "August 23, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Miami", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33136"
                }, 
                "name": "Clinical Research Building"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "The Effect of Whole-Food Dietary Supplementation on Cognitive and Immune Functioning and Quality of Life in Healthy Older Adults", 
        "overall_official": {
            "affiliation": "University of Miami", 
            "last_name": "John Lewis, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The measures included the MMSE, the Stroop Color and Word Test (SCWT), the Trail Making Test Parts A and B (TMT-A, TMT-B), the Controlled Oral Word Association test (COWA), the Digit Symbol subtest of the Wechsler Adult Intelligence Scale, Third Edition (WAIS-III), and the Hopkins Verbal Learning Test-Revised (HVLT-R)", 
            "measure": "Cognitive Measures", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01672359"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Miami", 
            "investigator_full_name": "John E. Lewis", 
            "investigator_title": "Director of Research", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Quality of Well-Being Scale (QWBS) Medical Outcomes Study Short Form 36 (SF 36) Beck Depression Inventory (BDI) Beck Anxiety Inventory (BAI)", 
                "measure": "Quality of Life Measures", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "interleukin [IL]-2, IL-4, IL-6, IL-8, IL-10, IL-1\u03b1, IL-1\u03b2, interferon [IFN]-\u03b3, tumor necrosis factor [TNF]-\u03b1, monocyte chemotactic protein [MCP]-1, vascular endothelial growth factor [VEGF], and epidermal growth factor [EGF]", 
                "measure": "Immune Function Markers", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "source": "University of Miami", 
        "sponsors": {
            "collaborator": {
                "agency": "Standard Process Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University of Miami", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2011", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}